{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:44:05Z","timestamp":1778928245207,"version":"3.51.4"},"reference-count":12,"publisher":"Scientific Scholar","content-domain":{"domain":["indianjnephrol.org"],"crossmark-restriction":true},"short-container-title":["Indian J Nephrol"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Intraperitoneal vancomycin is commonly used to treat peritoneal dialysis (PD)-related peritonitis. Therapeutic drug level monitoring helps optimize the use of vancomycin in CKD patients. We studied whether sufficient serum levels were achieved in patients with PD-related peritonitis treated with the commonly used dose of vancomycin in patients with end stage renal disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods<\/jats:title>\n<jats:p>All consecutive patients with PD-related peritonitis during 19 months were studied. Patients received IP Vancomycin 15 mg\/kg Q96H and amikacin 2 mg\/kg while awaiting culture reports. Vancomycin concentration in serum and dialysate was determined by a validated liquid chromatography-tandem mass spectrometry assay at 1, 12, 24, and 96 h. The primary outcome was the drug levels in serum and peritoneal fluid, and the secondary outcome was peritonitis treatment failure.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 45 episodes of PD-related peritonitis were treated, of which 41 fulfilled the inclusion criteria and were included in the PK analysis. Recommended serum vancomycin trough level of &gt;15 mg\/L was achieved in only two cases. Twenty-one episodes required catheter removal.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In patients with PD-related peritonitis, intermittent intraperitoneal administration of 15 mg\/kg of vancomycin every 96 h does not achieve the recommended serum and dialysate levels of vancomycin. There is an urgent need for pharmacokinetic studies on commonly used IP antibiotics in the PD population to facilitate correct dose recommendations.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijn_59_2024","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:09:14Z","timestamp":1726726154000},"page":"524-529","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intraperitoneally Administered Vancomycin Results in Suboptimal Serum and Peritoneal Effluent Drug Levels in Patients with PD-related Peritonitis"],"prefix":"10.25259","volume":"35","author":[{"given":"Ezhilnilavan","family":"Sampath","sequence":"first","affiliation":[{"name":"Department of Nephrology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), JIPMER Campus, Puducherry, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapil","family":"Navin Sejpal","sequence":"additional","affiliation":[{"name":"Department of Nephrology, JNMC & AVBRH, DMIHER, Sawangi, Wardha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurba S.","family":"Sastry","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), JIPMER Campus, Puducherry, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhiya","family":"Selvarajan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), JIPMER Campus, Puducherry, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.S.","family":"Priyamvada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), JIPMER Campus, Puducherry, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreejith","family":"Parameswaran","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), JIPMER Campus, Puducherry, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"10.25259\/IJN_59_2024\/ref-1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3747\/pdi.2010.00131","article-title":"Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients","volume":"31","author":"Ghali","year":"2011","journal-title":"Perit Dial Int"},{"key":"10.25259\/IJN_59_2024\/ref-2","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1681\/ASN.2011121135","article-title":"Recent peritonitis associates with mortality among patients treated with peritoneal dialysis","volume":"23","author":"Boudville","year":"2012","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.25259\/IJN_59_2024\/ref-3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/0896860819889774","article-title":"Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy","volume":"40","author":"Lam","year":"2020","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"10.25259\/IJN_59_2024\/ref-4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3747\/pdi.2013.00156","article-title":"The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis","volume":"35","author":"Stevenson","year":"2015","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"10.25259\/IJN_59_2024\/ref-5","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.2215\/CJN.00630117","article-title":"Residual kidney function and peritoneal dialysis\u2013associated peritonitis treatment outcomes","volume":"12","author":"Whitty","year":"2017","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.25259\/IJN_59_2024\/ref-6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3747\/pdi.2010.00049","article-title":"Peritoneal dialysis-related infections recommendations: 2010 update","volume":"30","author":"Li","year":"2010","journal-title":"Perit Dial Int"},{"key":"10.25259\/IJN_59_2024\/ref-7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/106002808802200114","article-title":"Absorption of intraperitoneal antibiotics","volume":"22","author":"Morse","year":"1988","journal-title":"Drug Intell Clin Pharm"},{"key":"10.25259\/IJN_59_2024\/ref-8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199018060-00005","article-title":"Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis","volume":"18","author":"Neal","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.25259\/IJN_59_2024\/ref-9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1128\/aac.31.2.173","article-title":"Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis","volume":"31","author":"Morse","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/IJN_59_2024\/ref-10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3747\/pdi.2010.00294","article-title":"Intraperitoneal vancomycin concentrations during peritoneal dialysis\u2013associated peritonitis: Correlation with serum levels","volume":"32","author":"Fish","year":"2012","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"10.25259\/IJN_59_2024\/ref-11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0272-6386(95)90132-9","article-title":"Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients","volume":"25","author":"Mulhern","year":"1995","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"10.25259\/IJN_59_2024\/ref-12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4212\/cjhp.v63i5.948","article-title":"Stability of vancomycin 25 mg\/mL in ora-sweet and water in unit-dose cups and plastic bottles at 4\u00b0C and 25\u00b0C","volume":"63","author":"Ensom","year":"2010","journal-title":"Can J Hosp Pharm"}],"container-title":["Indian Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/indianjnephrol.org\/intraperitoneally-administered-vancomycin-results-in-suboptimal-serum-and-peritoneal-effluent-drug-levels-in-patients-with-pd-related-peritonitis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/indianjnephrol.org\/intraperitoneally-administered-vancomycin-results-in-suboptimal-serum-and-peritoneal-effluent-drug-levels-in-patients-with-pd-related-peritonitis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:22:53Z","timestamp":1751300573000},"score":1,"resource":{"primary":{"URL":"https:\/\/indianjnephrol.org\/intraperitoneally-administered-vancomycin-results-in-suboptimal-serum-and-peritoneal-effluent-drug-levels-in-patients-with-pd-related-peritonitis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":12,"alternative-id":["10.25259\/IJN_59_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijn_59_2024","relation":{},"ISSN":["1998-3662","0971-4065"],"issn-type":[{"value":"1998-3662","type":"electronic"},{"value":"0971-4065","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"524"}}